发明名称 |
Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
摘要 |
Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-α production in mammals. |
申请公布号 |
US9468605(B2) |
申请公布日期 |
2016.10.18 |
申请号 |
US201414305082 |
申请日期 |
2014.06.16 |
申请人 |
Celgene Corporation |
发明人 |
Parikh Darshan K.;Menon Anil;Tutino Anthony |
分类号 |
A61K9/28;A61K31/4035;A61K9/20;A61K9/50 |
主分类号 |
A61K9/28 |
代理机构 |
Jones Day |
代理人 |
Jones Day |
主权项 |
1. An immediate-release oral dosage form comprising about 10-30% by weight of apremilast, about 40-50% by weight of lactose, about 20-30% by weight of cellulose, about 1-5% by weight of carboxymethyl cellulose, about 1-5% by weight of fumed silica and about 0.1-2% by weight of magnesium stearate and about 1-5% by weight of a coat, wherein about 100% of said apremilast is released in about 1 hour in an aqueous buffer solution of about pH 3 with a paddle speed of 75 rpm. |
地址 |
Summit NJ US |